Compare Amphastar Pharmaceuticals Inc (AMPH) vs Tidewater Inc (TDW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Tidewater Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Tidewater Inc trades at $74.39 (market cap $3.65B). The key difference: Tidewater Inc is far larger — about 4.4× Amphastar Pharmaceuticals Inc's market cap, and Tidewater Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | TDW | |
|---|---|---|
Market Cap | $826.08M | $3.65B |
Sector | Health | Utilities |
52-Week High | $30.81 | $91.12 |
52-Week Low | $16.87 | $46.32 |
Enterprise Value | $1.22B | $3.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Tidewater (TDW) trades at $73.37, up 3.84% with bullish technical signals from moving averages. The company maintains strong profitability with 22.16% net income margin and 24.03% ROE, though recent Q1 2026 earnings missed estimates. Valuation appears reasonable with P/E of 12.37 and EV/EBITDA of 9.15. Recent news includes FTAI Infrastructure's acquisition of Tidewater Logistics and mixed analyst sentiment.
The outlook remains cautiously optimistic given strong fundamentals but tempered by recent earnings misses. Investment opportunity lies in reasonable valuation and sector positioning, while risks include execution challenges and energy market volatility. Analyst consensus leans neutral with 61.54% hold ratings, suggesting balanced risk-reward profile.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
